OncoMatch/Clinical Trials/NCT06455072

Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer

Is NCT06455072 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Nituzumab and Serplulimab for cervical cancer.

Phase 2RecruitingFujian Cancer HospitalNCT06455072Data as of May 2026

Treatment: Nituzumab · Serplulimab — In recurrent advanced cervical cancer, patients were prone to drug resistance who have relapsed within prior platinum-based chemotherapy. However, immune checkpoint inhibitor's combination therapy has become a promising strategy for advanced cervical cancer. Epidermal Growth Factor Receptor (EGFR) is overexpressed in cervical cancer cells. Stereotactic radiotherapy (SBRT) can enhance the efficacy of immunotherapy.

Check if I qualify

Extracted eligibility criteria

Cancer type

Cervical Cancer

Biomarker criteria

Required: EGFR expression (testing required; no eligibility threshold specified)

consent providing sufficient tumor tissue samples for EGFR expression detection

Disease stage

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 1 prior line

Must have received: systemic therapy — persistent, recurrent, or metastatic cervical cancer

failure of standard systemic treatment for persistent, recurrent, or metastatic cervical cancer (defined as progression or recurrence within six months after at least one cycle of standard systemic treatment)

Cannot have received: anti-PD-1/PD-L1 antibody

Exception: patients who achieved CR, PR, or SD≥6 months may still be considered

patients who have previously received anti-PD-1/PD-L1 antibody treatment and achieved CR, PR, or SD≥6 months may still be considered

Cannot have received: anti-EGFR therapy (nintedanib)

previously received nintedanib or other anti-EGFR therapy

Cannot have received: tyrosine kinase inhibitor (sunitinib)

previously received sunitinib therapy

Cannot have received: anti-CTLA-4 antibody

previous treatment with anti-CTLA-4 antibody

Lab requirements

Blood counts

bone marrow hematopoietic function

Kidney function

good organ function

Liver function

good organ function

Good organ function and bone marrow hematopoietic function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify